Form 4: CRISPR CFO Reports Equity Grants, RSU Vesting & Tax Sale

CRISPR Therapeutics' CFO, Raju Prasad, disclosed new stock option and restricted stock unit grants, alongside a non-discretionary sale of shares to cover tax obligations.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG, reported several transactions.
• On March 20, 2026, 6,250 common shares were acquired through the vesting of restricted stock units.
• On March 23, 2026, 3,708 common shares were sold at $46.78 per share to cover tax withholding obligations related to RSU vesting, a non-discretionary sale mandated by company policy.
• A new stock option for 38,499 common shares was granted on March 20, 2026, with an exercise price of $46.24, vesting monthly over 48 months starting April 20, 2026, and expiring March 20, 2036.
• A new restricted stock unit award for 27,500 common shares was granted on March 20, 2026, vesting quarterly from March 20, 2027, to March 20, 2030.
• An additional 6,250 restricted stock units, part of a March 20, 2024 grant of 25,000 shares, vested on March 20, 2026.
• Following these transactions, Prasad directly beneficially owns 15,565 common shares, 38,499 stock options, and 27,500 restricted stock units (from the 2026 grant) and 12,500 restricted stock units (from the 2024 grant, remaining unvested).
• All shares are subject to a lock-up agreement related to the Issuer's convertible senior notes due 2031.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, reflecting routine executive compensation and a non-discretionary tax-related sale, which generally signals stability in management's long-term commitment.

Positives

• Grant of 38,499 stock options on March 20, 2026, indicating continued incentive for the CFO.
• Grant of 27,500 restricted stock units on March 20, 2026, further aligning CFO's interests with shareholders.
• Vesting of 6,250 restricted stock units on March 20, 2026, from a prior grant, increasing direct share ownership.

Negatives

• Sale of 3,708 common shares at $46.78 on March 23, 2026, reducing direct share ownership, although this was a non-discretionary tax-related sale.

Future Outlook

No explicit forward-looking statements or guidance are provided beyond the scheduled vesting of equity awards.

Industry Context

StockSavvy.ai notes that insider equity grants and vesting events are standard compensation practices in the biotechnology sector, particularly for key executives like a CFO. The non-discretionary sale for tax withholding is a common occurrence and typically not indicative of a change in management's outlook on the company's prospects. The lock-up agreement related to convertible notes is also a standard feature in such financing arrangements.

Comparison to Industry Standards

• Equity compensation packages, including stock options and restricted stock units, are a standard component of executive compensation across the biotechnology and pharmaceutical industries, comparable to practices at companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, aiming to align executive incentives with long-term shareholder value.
• The vesting schedules, particularly the 48-month monthly vesting for options and multi-year annual vesting for RSUs, are typical for executive grants, promoting long-term retention and performance.
• The non-discretionary sale of shares to cover tax obligations upon RSU vesting is a common and expected event for executives receiving equity compensation, mirroring practices observed at most publicly traded companies.

Stakeholder Impact

• Shareholders: The grants of equity to the CFO align his interests with long-term shareholder value. The tax-related sale is a routine event and not indicative of a change in sentiment. The lock-up agreement related to convertible notes impacts potential future dilution.
• Employees: The equity compensation structure for the CFO may reflect broader company-wide incentive programs, potentially impacting employee retention and motivation.

Next Steps

• Stock options will begin vesting in 48 equal monthly installments starting April 20, 2026.
• Restricted stock units granted on March 20, 2026, will vest quarterly on March 20, 2027, 2028, 2029, and 2030.
• Remaining restricted stock units from the March 20, 2024 grant will vest on March 20, 2027, and March 20, 2028.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation events (grants and vesting) and a non-discretionary sale for tax purposes. It does not contain new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment thesis. The grants are a positive for management alignment, but the tax sale is neutral. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide a strong catalyst for a "buy" or "sell" decision.

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Raju Prasad, CFO, Stock Option, Restricted Stock Units, RSU, Equity Grant, Tax Withholding, Convertible Senior Notes, Biotechnology, Gene Editing